Akebia Therapeutics (NASDAQ:AKBA) Downgraded to Sell Rating by StockNews.com
StockNews.com cut shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) from a hold rating to a sell rating in a research report released on Tuesday. Separately, HC Wainwright restated a “buy” rating and set a $7.50 price objective on shares of Akebia Therapeutics in a research note on Thursday, January 23rd. Read Our Latest Research […]
StockNews.com cut shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) from a hold rating to a sell rating in a research report released on Tuesday. Separately, HC Wainwright restated a “buy” rating and set a $7.50 price objective on shares of Akebia Therapeutics in a research note on Thursday, January 23rd. Read Our Latest Research […]
